期刊
ALZHEIMERS & DEMENTIA
卷 13, 期 5, 页码 541-549出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2016.08.012
关键词
Intellectual disability; Down syndrome; Alzheimer's disease; Blood biomarkers; Neuronal exosomes; Hyperphosphorylated tau; Amyloid-beta
资金
- Carlos III Institute of Health, Spain [PI11/02425, PI14/01126]
- CIBERNED program - FondoEuropeo de Desarrollo Regional (FEDER)
- CIBERNED program - Union Europea
- CIBERNED program - Una manera de hacer Europa
- Griffols Foundation [20141210]
- Fundacio Catalana de Sindrome de Down
- US National Institutes of Health [R01AG 21912, R01HD065160, UL1 TR00414, RO1AG04375, PO1AG14449]
- National Center for Research Resources
- National Center for Advancing Translational Sciences [UL1 TR000153]
Introduction: Individuals with Down syndrome (DS) exhibit Alzheimer's disease (AD) neuropathology and dementia early in life. Blood biomarkers of AD neuropathology would be valuable, as non-AD intellectual disabilities of DS and AD dementia overlap clinically. We hypothesized that elevations of amyloid beta (A beta) peptides and phosphorylated-tau in neuronal exosomes may document preclinical AD. Methods: AD neuropathogenic proteins A beta(1-42), P-T181-tau, and P-S396-tau were quantified by enzyme-linked immunosorbent assays in extracts of neuronal exosomes purified from blood of individuals with DS and age-matched controls. Results: Neuronal exosome levels of A beta(1-42), P-T181-tau, and P-S396-tau were significantly elevated in individuals with DS compared with age-matched controls at all ages beginning in childhood. No significant gender differences were observed. Discussion: These early increases in A beta(1-42), P-T181-tau, and P-S396-tau in individuals with DS may provide a basis for early intervention as targeted treatments become available. (C) 2016 Published by Elsevier Inc. on behalf of the Alzheimer's Association.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据